Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder?

Journal of Developmental and Behavioral Pediatrics

Volumn 30, Issue 2, 2009, Pages 158-168

  Waschbusch, Daniel A ^a   Pelham Jr , William E ^a   Waxmonsky, James ^b   Johnston, Charlotte ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ADHD; Literature review; Medication expectancies; Placebo effects

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; CAREGIVER; COGNITION; CONDITIONED REFLEX; DRUG EFFECT; DRUG RESPONSE; HEALTH BEHAVIOR; HUMAN; PLACEBO EFFECT; PRIORITY JOURNAL; REVIEW; CHILD; CHILD BEHAVIOR; CONDITIONING; EDUCATION; PARENT; PSYCHOLOGICAL ASPECT; SCHOOL; UNIVERSITY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD BEHAVIOR; COGNITION; CONDITIONING (PSYCHOLOGY); EDUCATION; FACULTY; HUMANS; PARENTS; PLACEBO EFFECT; PLACEBOS; SCHOOLS;

EID: 67649994706     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/DBP.0b013e31819f1c15     Document Type: Review

References (96)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th text revision ed. Washington, DC: American Psychiatric Association; 2000.
2. Pelham WE, Wheeler T, Chronis AM. Empirically supported psychosocial treatment for attention deficit hyperactivity disorder. J Clin Child Psychol. 1998;27:190-205.
3. Pelham WE, Fabiano GA. Evidence-based psychosocial treatment for attention-deficit/hyperactivity disorder: an update. J Clin Child Adolesc. 2008;37:184-214.
4. Pliszka SR, Greenhill LL, Crimson ML, et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. J Am Acad Child Adolesc Psychiatry. 2000;39:908-919. (Pubitemid 30429924)
5. NIH Consensus Statement. Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder. Kensington, MD: National Institutes of Health Consensus Development Project; 1998.
6. American Academy of Child, Adolescent Psychiatry. Practice parameters for the assessment, treatment of children, adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
7. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;105:1033-1044.
8. Children and adults with attention-deficit/hyperactivity disorder. Evidence-Based Medication Management for Children and Adolescents with AD/HD: CHADD fact sheet #3. Landover, MD; 2003:12.
9. Swanson JM, McBurnett K, Christian DL, Wigal T. Stimulant medications and the treatment of children with ADHD. In: Ollendick TH, Prinz RJ, eds. Advances in Clinical Child Psychology. Vol 17. New York: Plenum Press; 1995:265-322.
10. Greenhill LL, Ford RE. Childhood attention deficit hyperactivity disorder: pharmacological treatments. In: Nathan PE, Gorman JM, eds. A Guide to Treatments That Work. 2nd ed. New York: Oxford University Press; 2002:25-55.
11. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
12. Pelham WE. The NIMH multimodal treatment study for ADHD: just say yes to drugs? Clinical Child Psychology Newsletter. Vol 14. 1999:1-6.
13. Pelham WE. The NIMH Multimodal Treatment Study for attention-deficit hyperactivity disorder: just say yes to drugs? Can J Psychiatry. 1999;44:981-990. (Pubitemid 30062397)
14. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 2003;41:514-521.
15. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. J Am Med Assoc. 2000;283:1025-1030.
16. Miller AR, Lalonde CE, McGrail KM, Armstrong RW. Prescriptions of methylphenidate to children and youth, 1990- 1996. Can Med Assoc J. 2001;165:1489-1494.
17. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98: 1084-1088. (Pubitemid 26399270)
18. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood). 2007;26: 450-457.
19. Rowland AS, Umbach DM, Stallone L, Naftel AJ, Bohlig EM, Sandler DP. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health. 2002; 92:231-234. (Pubitemid 34101433)
20. Devilbliss DM, Berridge CW. Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness. Biol Psychiatry. 2008;64:626-635.
21. Carrey NJ, MacMaster FP, Fogel J, et al. Metabolite changes resulting from treatment in children with ADHD: a 1H-MRS study. Clin Neuropharmacol. 2003;26:218-221. (Pubitemid 36951069)
22. Castellanos FX. The psychobiology of attention-deficit/ hyperactivity disorder. In: Quay HC, Hogan AE, eds. Handbook of Disruptive Behavior Disorders. New York: Plenum Press; 1999:179-198.
23. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004;130: 324-340. (Pubitemid 38317814)
24. Koshi EB, Short CA. Placebo theory and its implications for research and clinical practice: a review of the literature. Pain Pract. 2007;7:4-20.
25. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565-590.
26. Brown WA. Understanding and using the placebo effect. Psychiatric Times. 2006;23:15-17.
27. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. J Am Med Assoc. 1994;271:1609-1614. (Pubitemid 24155623)
28. Sandler AD. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev. 2005;11:164-170. (Pubitemid 40981698)
29. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5:1223-1227.
30. Kirsch I. Yes, there is a placebo effect, but is there a powerful antidepressant drug effect? Prev Treat. 2002; 5:Article 22.
31. Wager TD, Rilling JK, Smith EE, et al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science. 2004;303:1162-1167.
32. Kirsch I, Weixel LJ. Double-blind versus deceptive administration of a placebo. Behav Neurosci. 1988;102:319-323. (Pubitemid 18213280)
33. Fernandes R, Ferreira JJ, Sampaio C. The placebo response in studies of acute migraine. J Pediatr. 2008;152:527-533.
34. Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005;45:232-239. (Pubitemid 40393213)
35. Khan A, Kolts RL, Rapaport MH, Krishnan KRR, Brodhead AE, Brown WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med. 2005;35: 743-749. (Pubitemid 40716438)
36. Grissom RJ. The magical number 7 ± 2: meta-analysis of the probability of superior outcome in comparisons involving therapy, placebo and control. J Consult Clin Psychol. 1996;64: 973-982. (Pubitemid 126753891)
37. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat. 1998; 1:Article 2.
38. Joffe RD, Sokolov S, Streiner D. Antidepression treatment of depression: a meta-analysis. Can J Psychiatry. 1996;41:613-616.
39. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc. 2002;287:1840-1847. (Pubitemid 34303629)
40. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ. 2004;328:879-883. (Pubitemid 38471402)
41. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG concordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry. 2006;163:1426-1432.
42. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat. 2002; 5: Article 23.
43. Birmaher B, Brent DA. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:1503-1526. (Pubitemid 351338971)
44. Teicher MH, Ito Y, Glod CA, Barber NI. Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatry. 1996;35:334-342. (Pubitemid 26072291)
45. Teicher MH, Polcari A, McGreenery CE. Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18:265-270.
46. Pelham WE. Pharmacotherapy for children with attention-deficit hyperactivity disorder. School Psych Rev. 1993;22:199-227.
47. Waschbusch DA, Hill GP. Alternative treatments for children with attention-deficit/hyperactivity disorder (ADHD): what does the research say? Behav Ther. 2001;24:161-171.
48. Sherman R, Hickner J. Academic physicians use placebos in clinical practice and believe in the mind-body connections. J Gen Intern Med. 2008;23:7-10.
49. Tilburt JC, Emanuel EJ, Kaptchuk TJ, Curlin FA, Miller FG. Prescribing "placebo treatments": results of a national survey of US internists and rheumatologists. BMJ. 2008;337:a1938.
50. Aschwanden C. Experts question placebo pill for children. The New York Times. May 27, 2008.
51. Ottenbacher KJ, Cooper MM. Drug treatment of hyperactivity in children. Dev Med Child Neurol. 1983;25:358-366.
52. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry. 1977;18:137-165. (Pubitemid 8092156)
53. Gittleman-Klein R. Diagnosis and drug treatment of childhood disorders: attention deficit disorder with hyperactivity. In: Klein RG, Quitkin F, eds. Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children. 2nd ed. Baltimore, MD: Williams & Wilkins; 1980.
54. Wilens TE, Biederman J. The stimulants. Psychiatric Clin North Am. 1992;15:191-222.
55. Schachar R, Tannock R. Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychopharmacol. 1993;3:81-97.
56. Fisher S, Greenberg RP. How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis. 1993;181: 345-350. (Pubitemid 24259604)
57. Ullman RK, Sleator EK. Responders, nonresponders, and placebo responders among children with Attention Deficit Disorder. Clin Pediatr. 1986;25:594-599.
58. Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. Child Care Health Develop. 2008;34:104-110.
59. Henker B, Whalen CK. Hyperactivity and attention deficits. Am Psychol. 1989;44:216-223.
60. Whalen CK, Henker B. Stimulant pharmacotherapy for attentiondeficit/ hyperactivity disorders: an analysis of progress, problems, and prospects. In: Fisher S, Greenberg RP, eds. From Placebo to Panacea. New York: Wiley; 1997:323-356.
61. Hull JG, Bond CF. Social and behavioral consequences of alcohol consumption and expectancy: a meta-analysis. Psychol Bull. 1986;99:347-360.
62. Pelham WE, Hoza B, Kipp HL, Gnagy EM, Trane SE. Effects of methylphenidate and expectancy on ADHD children's performance, self evaluations, persistence, and attributions on a cognitive task. Exp Clin Psychopharmacol. 1997;5:1-11. (Pubitemid 27087312)
63. Pelham WE, Waschbusch DA, Hoza B, Pillow DR, Gnagy EM. Effects of methylphenidate and expectancy on ADHD boys' performance, self-evaluations, persistence, and attributions on a social task. Exp Clin Psychopharmacol. 2001;9:425-437. (Pubitemid 33117494)
64. Pelham WE, Hoza B, Pillow DR, et al. Effects of methylphenidate and expectancy on children with ADHD: behavior, academic performance, and attributions in a Summer Treatment Program and regular classroom setting. J Consult Clin Psychol. 2002;70: 320-335. (Pubitemid 34274876)
65. Ialongo NS, Lopez M, Horn WF, Pascoe JM, Greenberg G. Effects of psychostimulant medication on self-perceptions of competence, control, and mood in children with attention deficit hyperactivity disorder. J Clin Child Psychol. 1994;23:161-173. (Pubitemid 24799347)
66. Pelham WE, Murphy DA, Vanatta K, et al. Methylphenidate and attributions in boys with attention deficit hyperactivity disorder. J Consult Clin Psychol. 1992;60:282-292.
67. Carlson CL, Pelham WE, Milich R, Hoza B. ADHD boys' performance and attributions following success and failure: drug effects and individual differences. Cognit Ther Res. 1993;17: 269-287. (Pubitemid 23227537)
68. Hoover DW, Milich R. Effects of sugar ingestion expectancies on mother-child interactions. J Abnorm Child Psychol. 1994;22: 501-515. (Pubitemid 24256512)
69. Borden KA, Brown RT. Attributional outcomes: the subtle messages of treatments for attention-deficit disorder. Cognit Ther Res. 1989;13:147-160.
70. Evans SW, Pelham WE, Smith BH, et al. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharamcol. 2001;9:163-175.
71. Smith BH, Pelham WE, Evans SW, et al. Dosage effects on methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol. 1998;6:187-204.
72. Nichols S, Waschbusch DA. A review of the validity of laboratory cognitive tasks used to assess symptoms of ADHD. Child Psychiatry Hum Dev. 2004;34:297-315. (Pubitemid 38992977)
73. Barkley RA. The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. J Abnorm Child Psychol. 1991;19:149-178.
74. Pelham WE, Fabiano GA, Massetti GM. Evidence-based assessment for attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc. 2005;34:449-476. (Pubitemid 41355524)
75. Pelham WE, Burrows-MacLean L, Gnagy EM, et al. Behavioral and pharmacological treatment for children with ADHD. Paper presented at: Annual Convention of the American Psychological Association; August, 2005; Washington, DC.
76. Fabiano GA, Pelham WE, Gnagy EM, et al. The single and combined effects of multiple intensities of behavior modification and multiple intensities of methylphenidate for children with attention deficit hyperactivity disorder in a classroom setting. School Psych Rev. 2007;36:195-216.
77. Pelham WE, Milich R, Murphy DA, Murphy HA. Normative data on the IOWA Conners teacher rating scale. J Clin Child Psychol. 1989;18:259-262.
78. Waschbusch DA, Willoughby MT. Parent and teacher ratings on the IOWA Conners Rating Scale. J Psychpathol Behav. 2008;30: 180-192.
79. Fabiano GA, Pelham WE, Waschbusch DA, et al. A practical impairment measure: psychometric properties of the Impairment Rating Scale in samples of children with attentiondeficit/ hyperactivity disorder and two school-based samples. J Clin Child Adolesc. 2006;35:369-385.
80. Pillow DR, Flannagan D. A report to participants from the UTSA ADHD research project. Available at: http://colfa.utsa.edu/users/ dpillow/adhdfind.htm. Accessed: February 26, 2009.
81. Johnston C, Reynold S, Freeman WS, Geller J. Assessing parent attributions for child behavior: using open-ended questions. J Clin Child Psychol. 1998;27:87-97.
82. Collett BR, Gimpel GA. Maternal and child attributions in ADHD versus non-ADHD populations. J Atten Disord. 2004;7:187-196.
83. Johnston C, Fine S, Weiss M, Weiss J, Weiss G, Freeman WS. Effects of stimulant medication treatment on mothers' and children's attributions for the behavior of children with attention deficit hyperactivity disorder. J Abnorm Child Psychol. 2000;28:371-382. (Pubitemid 30614827)
84. Ohan JL, Johnston C. Attributions in adolescents medicated for attention-deficit/hyperactivity disorder. J Atten Disord. 1999;3: 49-60.
85. Johnston C, Leung DW. Effects of medication, behavioral, and combined treatments on parents' and children's attributions for the behavior of children with attention-deficit hyperactivity disorder. J Consult Clin Psychol. 2001;69:67-76. (Pubitemid 32210055)
86. Coles EK, Pelham WE, Gnagy EM. Assessing parental attributions for success and failure in managing deviant child behavior. Poster presented at the 37th annual convention of the Association for the Advancement of Behavior Therapy. Boston, MA; 2003.
87. Antonuccio DA, Burns DD, Danton WG. Antidepressants: a triumph of marketing over science? Prev Treat. 2002;5: Article 25.
88. Johnston C, Ohan JL. The importance of parental attributions in families of children with attention-deficit/hyperactivity and disruptive behavior disorders. Clin Child Fam Psych. 2005;8:167-182. (Pubitemid 44289416)
89. Chronis AM, Lahey BB, Pelham WE, Kipp HL, Baumann BL, Lee SS. Psychopathology and substance abuse in parents of young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003;42:1424-1432. (Pubitemid 39585972)
90. Cunningham CE, Boyle M. Preschoolers at risk for attention deficit hyperactivity disorder and oppositional defiant disorder: family, parenting, and educational correlates. J Abnorm Child Psychol. 2002;30:555-569. (Pubitemid 38457415)
91. Mash EJ, Johnston C. Determinants of parenting stress: illustrations from families of hyperactive children and families of physically abused children. J Clin Child Psychol. 1990;19:313-328.
92. Barkley RA. Defiant Children: A Clinician's Manual for Parent Training. New York, NY: Guilford Press; 1987.
93. Cunningham CE, Bremner R, Boyle M. Large group community-based parenting programs for families of preschoolers at risk for disruptive behavior disorders: utilization, cost effectiveness, and outcome. J Child Psychol Psychiatry. 1995;36:1141-1159.
94. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Rintlemann J. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-1037. (Pubitemid 27476099)
95. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205-1215.
96. Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized-controlled trial. J Am Med Assoc. 2004;297:807-820.